Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Malignant Lymphoma

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 33 articles: HTML format

Single Articles

September 2023
1. WANG F, Palmer N, Fox K, Liao KP, et al
   Large-scale real-world data analyses of cancer risks among patients with rheumatoid arthritis.
   Int J Cancer. 2023;153:1139-1150.
   PubMed     Abstract available
   
   
   
2. MANGIATERRA TS, De Dios Soler M, Oviedo N, Colli S, et al
   Presence of EBV antigens detected by a sensitive method in pediatric and adult Diffuse Large B-cell lymphomas.
   Int J Cancer. 2023;153:1043-1050.
   PubMed     Abstract available
   
   
   
3. SIRIRUNGREUNG A, Hansen J, Ritz B, Heck JE, et al
   Association between medically diagnosed postnatal infection and childhood cancers: A matched case-control study in Denmark, 1978 to 2016.
   Int J Cancer. 2023;153:994-1002.
   PubMed     Abstract available
   
   
   August 2023
4. WEI YC, Qi F, Zheng BM, Zhang CG, et al
   Intensive therapy can improve long-term survival in newly diagnosed, advanced-stage extranodal NK/T-cell lymphoma: A multi-institutional, real-world study.
   Int J Cancer. 2023 Aug 4. doi: 10.1002/ijc.34672.
   PubMed     Abstract available
   
   
   June 2023
5. ZENG D, Fang Y, Fei Y, Liang R, et al
   Treatment patterns and clinical outcomes of mantle cell lymphoma: a retrospective cohort study by CHOICE.
   Int J Cancer. 2023 Jun 6. doi: 10.1002/ijc.34619.
   PubMed    
   
   
   
6. MBURU W, Devesa SS, Check D, Shiels MS, et al
   Incidence of Burkitt lymphoma in the United States during 2000 to 2019.
   Int J Cancer. 2023 Jun 6. doi: 10.1002/ijc.34618.
   PubMed     Abstract available
   
   
   
7. XIAO H, Wang S, Tang Y, Li S, et al
   Absence of terminal deoxynucleotidyl transferase expression in T-ALL/LBL accumulates chromosomal abnormalities to induce drug resistance.
   Int J Cancer. 2023;152:2383-2395.
   PubMed     Abstract available
   
   
   May 2023
8. ZENG D, Fang Y, Fei Y, Liang R, et al
   Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE.
   Int J Cancer. 2023 May 19. doi: 10.1002/ijc.34565.
   PubMed     Abstract available
   
   
   
9. CHOLUJOVA D, Beke G, Hunter ZR, Hideshima T, et al
   Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenstrom macroglobulinemia.
   Int J Cancer. 2023;152:1947-1963.
   PubMed     Abstract available
   
   
   April 2023
10. ENTROP JP, Weibull CE, Smedby KE, Jakobsen LH, et al
    Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study.
    Int J Cancer. 2023 Apr 29. doi: 10.1002/ijc.34552.
    PubMed     Abstract available
    
    
    December 2022
11. KOTCHETKOV R, Drennan IR, Susman D, DiMaria E, et al
    Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin's lymphoma and Mantle Cell Lymphoma in elderly: A single center observational study.
    Int J Cancer. 2022 Dec 22. doi: 10.1002/ijc.34412.
    PubMed     Abstract available
    
    
    November 2022
12. WANG Z, Phillips LS, Rohan TE, Ho GY, et al
    Diabetes, Metformin Use, and Risk of Non-Hodgkin's Lymphoma in Postmenopausal Women: A Prospective Cohort Analysis in the Women's Health Initiative.
    Int J Cancer. 2022 Nov 28. doi: 10.1002/ijc.34376.
    PubMed     Abstract available
    
    
    September 2022
13. RHEE J, Birmann BM, De Roos AJ, Epstein MM, et al
    Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: a pooled analysis.
    Int J Cancer. 2022 Sep 24. doi: 10.1002/ijc.34299.
    PubMed     Abstract available
    
    
    
14. ELVERDI T, Hiyamli MF, Sahin B, Eskazan AE, et al
    A new dawn for upfront autologous SCT in NK/T-cell lymphomas: One more step forward in reasoning.
    Int J Cancer. 2022;151:661-664.
    PubMed    
    
    
    August 2022
15. BOYLE T, Kleinstern G, Bracci PM, Cerhan JR, et al
    Physical activity and the risk of non-Hodgkin lymphoma subtypes: a pooled analysis.
    Int J Cancer. 2022 Aug 27. doi: 10.1002/ijc.34266.
    PubMed     Abstract available
    
    
    June 2022
16. YARMOLINSKY J, Amos CI, Hung RJ, Moreno V, et al
    Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk.
    Int J Cancer. 2022 Jun 23. doi: 10.1002/ijc.34180.
    PubMed     Abstract available
    
    
    
17. MAFRA A, Laversanne M, Gospodarowicz M, Klinger P, et al
    Global patterns of non-Hodgkin lymphoma in 2020.
    Int J Cancer. 2022 Jun 13. doi: 10.1002/ijc.34163.
    PubMed     Abstract available
    
    
    April 2022
18. ABRAHAO R, Cooley JJP, Maguire FB, Parikh-Patel A, et al
    Stage at diagnosis and survival among adolescents and young adults with lymphomas following the Affordable Care Act implementation in California.
    Int J Cancer. 2022;150:1113-1122.
    PubMed     Abstract available
    
    
    January 2022
19. SINGH D, Vaccarella S, Gini A, Silva NP, et al
    Global patterns of Hodgkin lymphoma incidence and mortality in 2020 and a prediction of the future burden in 2040.
    Int J Cancer. 2022 Jan 26. doi: 10.1002/ijc.33948.
    PubMed     Abstract available
    
    
    December 2021
20. YOSHIDA-SAKAI N, Watanabe T, Yamamoto Y, Ureshino H, et al
    Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.
    Int J Cancer. 2021 Dec 16. doi: 10.1002/ijc.33901.
    PubMed     Abstract available
    
    
    
21. JI J, Liu Z, Kuang P, Dong T, et al
    A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas.
    Int J Cancer. 2021;149:2075-2082.
    PubMed     Abstract available
    
    
    
22. FOUNTZILAS C, Adjei A, Opyrchal M, Evans R, et al
    A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors.
    Int J Cancer. 2021;149:2063-2074.
    PubMed     Abstract available
    
    
    October 2021
23. WU J, Song Y, Chen X, Lin T, et al
    Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: extended follow-up of the multicenter, single-arm, phase 2 study.
    Int J Cancer. 2021 Oct 21. doi: 10.1002/ijc.33852.
    PubMed     Abstract available
    
    
    
24. MPUNGA T, Clifford GM, Morgan EA, Milner DA Jr, et al
    Epstein-Barr virus prevalence among subtypes of malignant lymphoma in Rwanda, 2012-2018.
    Int J Cancer. 2021 Oct 9. doi: 10.1002/ijc.33840.
    PubMed     Abstract available
    
    
    September 2021
25. SHEN Z, Hu L, Yao M, He C, et al
    Disparity analysis and prognostic value of pretreatment whole blood Epstein-Barr virus DNA load and EBER status in lymphomas: A retrospective multicenter study in Huaihai Lymphoma Working Group.
    Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33802.
    PubMed     Abstract available
    
    
    July 2021
26. DE ROOS AJ, Schinasi LH, Miligi L, Cerhan JR, et al
    Occupational Insecticide Exposure and Risk of Non-Hodgkin Lymphoma: A Pooled Case-Control Study from the InterLymph Consortium.
    Int J Cancer. 2021 Jul 16. doi: 10.1002/ijc.33740.
    PubMed     Abstract available
    
    
    June 2021
27. HERDA S, Heimann A, Obermayer B, Ciraolo E, et al
    Long-term in vitro expansion ensures increased yield of central memory T cells as perspective for manufacturing challenges.
    Int J Cancer. 2021;148:3097-3110.
    PubMed     Abstract available
    
    
    
28. JAQUET A, Boni SP, Boidy K, Tine J, et al
    Chronic viral hepatitis, HIV infection and Non-Hodgkin lymphomas in West Africa, a case-control study.
    Int J Cancer. 2021 Jun 14. doi: 10.1002/ijc.33709.
    PubMed     Abstract available
    
    
    
29. PARKIN DM, Youlden DR, Chitsike I, Chokunonga E, et al
    Stage at diagnosis and survival by stage for the leading childhood cancers in three populations of sub-Saharan Africa.
    Int J Cancer. 2021;148:2685-2691.
    PubMed     Abstract available
    
    
    April 2021
30. SHI Z, Wei J, Na R, Resurreccion WK, et al
    Cystic fibrosis F508del carriers and cancer risk: Results from the UK Biobank.
    Int J Cancer. 2021;148:1658-1664.
    PubMed     Abstract available
    
    
    
31. SOLIMAN RM, Elhaddad A, Oke J, Eweida W, et al
    Temporal trends in childhood cancer survival in Egypt, 2007 to 2017: A large retrospective study of 14 808 children with cancer from the Children's Cancer Hospital Egypt.
    Int J Cancer. 2021;148:1562-1574.
    PubMed     Abstract available
    
    
    March 2021
32. GAUT D, Tang K, Sim MS, Duong T, et al
    Filgrastim associations with CAR T-cell therapy.
    Int J Cancer. 2021;148:1192-1196.
    PubMed     Abstract available
    
    
    November 2020
33. JIANG S, Qin Y, Jiang H, Liu B, et al
    Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
    Int J Cancer. 2020;147:2611-2620.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: